- Home
- BBT vs LIVN Comparison
BBT vs LIVN Comparison
Compare BBT & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBT
- LIVN
- Stock Information
- Founded
- BBT 1846
- LIVN 1987
- Country
- BBT United States
- LIVN United Kingdom
- Employees
- BBT N/A
- LIVN N/A
- Industry
- BBT Banks
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BBT Finance
- LIVN Health Care
- Exchange
- BBT Nasdaq
- LIVN Nasdaq
- Market Cap
- BBT 2.0B
- LIVN 2.1B
- IPO Year
- BBT N/A
- LIVN 1993
- Fundamental
- Price
- BBT $24.52
- LIVN $54.72
- Analyst Decision
- BBT Buy
- LIVN Strong Buy
- Analyst Count
- BBT 2
- LIVN 7
- Target Price
- BBT $33.00
- LIVN $59.71
- AVG Volume (30 Days)
- BBT 847.3K
- LIVN 426.3K
- Earning Date
- BBT 10-29-2025
- LIVN 11-05-2025
- Dividend Yield
- BBT N/A
- LIVN N/A
- EPS Growth
- BBT N/A
- LIVN N/A
- EPS
- BBT 2.10
- LIVN N/A
- Revenue
- BBT $345,393,000.00
- LIVN $1,309,329,000.00
- Revenue This Year
- BBT $58.22
- LIVN $10.10
- Revenue Next Year
- BBT $61.27
- LIVN $7.83
- P/E Ratio
- BBT $11.72
- LIVN N/A
- Revenue Growth
- BBT 8.11
- LIVN 8.23
- 52 Week Low
- BBT $22.27
- LIVN $32.48
- 52 Week High
- BBT $32.36
- LIVN $58.91
- Technical
- Relative Strength Index (RSI)
- BBT N/A
- LIVN 55.67
- Support Level
- BBT N/A
- LIVN $53.73
- Resistance Level
- BBT N/A
- LIVN $55.32
- Average True Range (ATR)
- BBT 0.00
- LIVN 1.25
- MACD
- BBT 0.00
- LIVN 0.28
- Stochastic Oscillator
- BBT 0.00
- LIVN 87.27
About BBT Beacon Financial Corporation Common stock
Beacon Financial Corp operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.